Straits Times Index
3,339.13 -9.74 (-0.29%) S&P 500
5,283.40 +5.89 (+0.11%) Dow
38,571.03 -115.27 (-0.30%) Nasdaq
16,828.67 +93.67 (+0.56%) Bitcoin USD
68,828.49 -305.03 (-0.44%) CMC Crypto 200
1,446.95 -0.20 (-0.01%)
Kintara Therapeutics, Inc. (KTRA)
Pre-market:
- PR Newswire
TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy and Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced positive results from the primary analysis of TuHURA's completed Phase 1b trial evaluating IFx-2.0 among patients with advanced or metastatic MCC or cSCC who exhibite
- PR Newswire
Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results
Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal third quarter ended March 31, 2024, and recent corporate developments.
- Zacks
Kintara (KTRA) Stock Soars on Merger Agreement With TuHURA
Kintara (KTRA) inks a definitive merger agreement with TuHURA for an all-stock transaction. It is expected to close in the third quarter of 2024. The stock surges 63.4%.
